How Viable Is The Future Of The “Traditional” CGM?
Executive Summary
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
You may also be interested in...
Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
Paige Secures Eighth CE Mark For Cancer Identification AI
The Memorial Sloan Kettering spin-out has received CE-IVD and UKCA marks for its artificial intelligence software designed to identify HER2 expression in biopsies.
What Do Speedboats Have To Do with Surgery?
Nothing except a name, but Creo Medical says its Speedboat Inject device can turn some surgeries from prolonged hospital stays into one-day visits.